Lista de obras - Dario Sangiolo - Dominio Público Uruguay

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

artículo científico

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma

artículo científico publicado en 2014

Adoptive immunotherapy against ovarian cancer

artículo científico publicado en 2016

Adoptive immunotherapy against sarcomas.

artículo científico publicado en 2014

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

artículo científico publicado en 2006

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers

scientific article published on 09 May 2008

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

artículo científico publicado en 2017

BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.

artículo científico publicado en 2018

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

scientific article published on 11 June 2019

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

artículo científico publicado en 2018

CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

artículo científico publicado en 2020

Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?

artículo científico publicado en 2011

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy

artículo científico publicado en 2018

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.

artículo científico publicado en 2009

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

artículo científico publicado en 2016

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

artículo científico

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives

artículo científico

Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition

artículo científico publicado en 2015

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

artículo científico publicado en 2013

Delving into PARP inhibition from bench to bedside and back

artículo científico publicado en 2019

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

artículo científico publicado en 2013

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers

artículo científico publicado en 2012

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.

artículo científico publicado en 2014

Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks ⬇️

artículo científico publicado el 7 de marzo de 2011

Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.

artículo científico publicado en 2014

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

artículo científico publicado en 2020

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

article

Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.

artículo científico

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

artículo científico publicado en 2017

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity

artículo científico publicado en 2016

Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.

artículo científico publicado en 2007

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

scientific article published on 06 February 2019

Next generation immune-checkpoints for cancer therapy.

artículo científico publicado en 2018

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

artículo científico publicado en 2017

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

artículo científico publicado en 2016

Recent advances in the development of breast cancer vaccines

artículo científico publicado en 2014

Redirected T cells in cancer therapy.

artículo científico publicado en 2015

Role of interferon in melanoma: old hopes and new perspectives.

artículo científico publicado en 2017

Significance of TIM3 expression in cancer: From biology to the clinic

scientific article published on 01 August 2019

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

artículo científico publicado en 2014

Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect

artículo científico publicado en 2018

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

artículo científico

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

artículo científico publicado en 2009

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

artículo científico publicado en 2013

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

artículo científico publicado en 2015

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

article

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.

artículo científico publicado en 2018

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

artículo científico publicado en 2011

Treating breast cancer with cell-based approaches: an overview.

artículo científico publicado en 2017

Treatment of metastatic melanoma: a multidisciplinary approach

artículo científico publicado en 2017

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.

artículo científico publicado en 2017

Veliparib: a new therapeutic option in ovarian cancer?

scientific article published on 10 May 2019

Lista de obras de Dario Sangiolo

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma

Adoptive immunotherapy against ovarian cancer

Adoptive immunotherapy against sarcomas.

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives

Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition

Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.

Delving into PARP inhibition from bench to bedside and back

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.

Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks ⬇️

Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity

Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

Next generation immune-checkpoints for cancer therapy.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

Recent advances in the development of breast cancer vaccines

Redirected T cells in cancer therapy.

Role of interferon in melanoma: old hopes and new perspectives.

Significance of TIM3 expression in cancer: From biology to the clinic

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

Treating breast cancer with cell-based approaches: an overview.

Treatment of metastatic melanoma: a multidisciplinary approach

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.

Veliparib: a new therapeutic option in ovarian cancer?